Related Experiment Video

Updated: May 14, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and

H K Ho1, G Németh, Y R Ng

  • 1Singapore OncoGenome Laboratory, Institute of Medical Biology, A*STAR, Singapore. phahohk@nus.edu.sg

Current Medicinal Chemistry
|February 16, 2013
PubMed

Insights

Researchers discovered novel inhibitors for Fibroblast Growth Factor Receptor-4 (FGFR4), a cancer-associated tyrosine kinase. The potent compound V4-015 shows promise for anti-cancer drug design by inhibiting FGFR4 activity and cell proliferation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Fibroblast Growth Factor Receptor-4 (FGFR4) is a tyrosine kinase implicated in various cancers.
  • FGFR4 mutations present a therapeutic target, but specific inhibitors are lacking for detailed study.
  • Lack of specific inhibitors hinders the characterization of FGFR4's role in disease and its therapeutic potential.

Purpose of the Study:

  • To discover novel, potent inhibitors for Fibroblast Growth Factor Receptor-4 (FGFR4) using a combined computational and experimental approach.
  • To identify chemical scaffolds with significant FGFR4 inhibitory capacity for future anti-cancer drug development.
  • To validate the efficacy of identified inhibitors in cellular assays relevant to cancer treatment.

Main Methods:

  • Utilized in silico docking against homologous FGFR1 to screen a diverse library of kinase inhibitors.
  • Conducted in vitro kinase assays to evaluate the inhibitory activity of selected compounds against FGFR4.
  • Performed cell-based assays using FGFR4-overexpressing breast cancer cells (MDA-MB453) to assess anti-proliferative and mechanistic effects.

Main Results:

  • Identified several compounds that significantly inhibit FGFR4 kinase activity, with V4-015 exhibiting sub-micromolar potency (IC50 = 0.04 μM).
  • Four compounds demonstrated cellular activity, inhibiting FGFR substrate protein-2α (FRS2α) phosphorylation in MDA-MB453 cells.
  • The lead compound V4-015 suppressed proliferation, activated caspases 3/7, and inhibited migration in MDA-MB453 cells at sub-micromolar concentrations.

Conclusions:

  • Successfully identified novel chemical scaffolds with potent FGFR4 inhibitory activity.
  • The potent inhibitor V4-015 demonstrates anti-cancer effects in cellular models, supporting its potential as a therapeutic lead.
  • These findings provide crucial tools for further mechanism of action studies and the development of targeted anti-cancer therapies.

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...